Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nextleaf Solutions Ltd C.OILS

Alternate Symbol(s):  OILFF

Healthcare Cannabis Health Care Cannabis
Nextleaf is a federally regulated manufacturer and distributor of cannabis vapes and oils under its prohibition-era brand, Glacial Gold. The Company’s multi-patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. Nextleaf is a low-cost producer of cannabis oils, and supplies THC and CBD ingredients to partners across Canada. Nextleaf has been issued 19 U.S. patents and over 100 patents globally, on cannabinoid processing.


CSE:OILS - Post by User

Nextleaf Solutions Ltd > Q3
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(582)
•••
Comment by shnepson Aug 31, 2022 8:32am
224 Views
Post# 34931794

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Q3

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Q3Revenues were not where we had hoped but I also see the expenses and debt being taken control of and reduced.
Still going through "lumpy" bulk sales which need to be smoothed out.
With overall market considerations, including declining national cannabis sales, I'm ok with the results but definitely want to see this sales team expenses justified.
Produce or cutback, pretty simple.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities